Facing Steepest Patent Cliff, Lilly's Outlook Gets Lowered
On the eve of reporting third-quarter earnings, Eli Lilly and Co. confronted a storm warning from Fitch Ratings, which affirmed the big pharma's ratings – including the issuer default rating (IDR) – at "A" but lowered its outlook on the company from "stable" to "negative."
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter